Article Text
Abstract
Diabetes mellitus is a common condition associated with numerous complications and comorbidities. The diabetes spectrum includes type 1, type 2 and other forms of diabetes, which may be associated with medical therapies and genetic factors. Type 2 diabetes is managed with lifestyle, oral therapies, non-insulin-based injectables and subsequently insulin. Type 1 diabetes requires insulin from the time of diagnosis. In recent years, there have been considerable developments in the therapies available to treat type 2 diabetes and some of these also afford cardiorenal protection. This review summarises the nature, complications and therapeutic advances in the field of diabetes and provides a concise review for neurologists. Managing diabetes optimally prevents complications and all medical specialties need a basic understanding of the principles involved in diabetes care.
- diabetes mellitus
Data availability statement
No data are available.
Statistics from Altmetric.com
Linked Articles
- Highlights from this issue
Read the full text or download the PDF:
Other content recommended for you
- New advances in type 1 diabetes
- Current management of diabetes mellitus and future directions in care
- Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial)
- Advances in the management of diabetes: new devices for type 1 diabetes
- Novel therapies for diabetes mellitus in pregnancy
- Advances in the management of type 2 diabetes in adults
- Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus
- Diabetic ketoacidosis with SGLT2 inhibitors
- HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment
- Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study